奥翔药业欧洲市场拓展获进展 股价近期震荡持平

Group 1 - The core point of the article is that Aoxiang Pharmaceutical has made significant progress in expanding its market in Europe with the approval of its partner STADA Arzneimittel AG's subsidiary for the marketing of tofacitinib citrate tablets, projected to generate global sales of $1.168 billion in 2024 [1] - The company has invested approximately 6.96 million yuan in research and development, indicating a commitment to innovation and product development [1] - Aoxiang Pharmaceutical has been re-certified as a high-tech enterprise, which will allow it to benefit from tax incentives and other policy support for three years [1] Group 2 - In the past week (February 5 to 11, 2026), Aoxiang Pharmaceutical's stock price remained stable with a fluctuation range of 0.51%, reaching a high of 9.99 yuan and a low of 9.80 yuan on February 6 [2] - As of the market close on February 11, the stock price was 9.87 yuan, with a net outflow of 2.4335 million yuan in main capital and a turnover rate of 0.46% [2] - Technical indicators show that the stock price is between the 20-day resistance level of 10.27 yuan and the support level of 9.59 yuan, with the MACD indicator showing weakness [2] Group 3 - The company's Q3 2025 financial report indicates a revenue of 646 million yuan for the first three quarters, a year-on-year decrease of 6.40%, and a net profit attributable to shareholders of 207 million yuan, down 9.59% year-on-year [3] - In Q3 alone, the revenue was 164 million yuan, reflecting a year-on-year decline of 17.01%, with a net profit of 37.6858 million yuan, down 23.33% year-on-year [3] - The decline in revenue and profit is primarily attributed to intensified competition in cardiovascular products and increased R&D expenses, with a Q3 R&D expense ratio of 15.41% [3]